SLS - ערך שוק SELLAS Life Sciences Group

SELLAS Life Sciences (SLS) is accelerating the development of anti-tumor agents using AI modeling and automated synthesis, although final testing remains the responsibility of medical professionals. The business relies on the development of immune vaccines against leukemia and solid tumors, which minimizes research risks. Market capitalization stands at 2.45. The market price chart below illustrates the price action of the asset, whose value could rise upon FDA approval of its unique therapy.

Market capitalization aggregates the current value of all shares, providing a real-time assessment of the business without the delays of financial reporting. This indicator measures the aggregate market demand for the issuer's assets. For SELLAS Life Sciences (SLS), the company's market capitalization reflects investment confidence in the success of joint oncology developments and immunotherapy alliances. This chart allows for the rapid tracking of shifting risks. The stable scale of this metric confirms the fundamental resilience of the innovation model.